A Phase 3 interventional study of migalastat HCl 150 mg in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 28 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-21.
Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.
Among the 20 studies testing migalastat in Fabry Disease, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 11 in phase 3, and was the 13th registered.
244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.
Browse Fabry Disease studies →2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:
Idorsia Pharmaceuticals Ltd. · Sites in United States, Canada, France and 2 more countries
Ages 18–60 · Men only
Amicus Therapeutics · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–11
By country, each count listing its studies:
migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2015.
This study's enrollment of 84 is above the median of 22 across 108 interventional studies indexed under Fabry Disease.
Median enrollment 20 across the 20 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Amicus Therapeutics, one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Amicus Therapeutics is the lead sponsor of 42 studies on the registry; 8 are open to participants now.
26 studies in Fabry Disease by BioMarin Pharmaceutical: 3 open now, 4 under way, 2 of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 2nd largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2015, is one of 8 in phase 3, and was the 16th registered.
BioMarin Pharmaceutical’s Fabry Disease studies by the year they started, since 2006.
1 of the studies testing migalastat in Fabry Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing migalastat in Fabry Disease, from their registry updates:
Among BioMarin Pharmaceutical’s 26 in Fabry Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Migalastat HCl 150 milligram (mg).
Drug: migalastat HCl 150 mg
Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
Also known as: AT1001, Galafold
Number Of Participants Experiencing Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered migalastat that did not necessarily have a causal relationship with the treatment. Each AE was recorded at time of reporting; visits typically occurred every 6 months. Serious AEs were life threatening or resulted in death, resulted in disability/incapacity, hospitalization or prolonged hospitalization, or a congenital anomaly. The criteria for AE severity were: Mild: awareness of sign or symptom, does not interfere with normal everyday activities; Moderate: discomforting, interferes with normal everyday activities, but able to function; Severe: incapacitating, prevents normal everyday activities or significantly affects clinical status and requires medical intervention. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Time frame: Day 1 after first dose to approximately 30 days after last treatment, median duration of 3.1 years
Annualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)
The annualized rate of change in the eGFR was assessed per participant by the slope of the simple linear regression between the observed values and the assessment times. It was calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (eGFR \[CKD-EPI\]) and the Modification of Diet in Renal Disease (MDRD) equation (eGFR \[MDRD\]). The equations are as follows: eGFR \[MDRD\] = 175 × (1/Serum Creatinine in mg/deciliter\^1.154) × (1/Age in years\^0.203) × 0.742 \[if female\] × 1.212 \[if black\] × 0.808 \[if Japanese\]; eGFR \[CKD-EPI\] = 141 × min(Serum creatinine \[Scr\]/k, 1)α × max(Scr/k, 1) - 1.209 × 0.993Age × 1.018 \[if female\] × 1.159 \[if black\], where Scr is serum creatinine, k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1. Participants with at least a Baseline and a post-Baseline value are presented.
Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Change From Baseline In eGFR At End Of Study
The change from baseline in eGFR was calculated using eGFR\[CKD-EPI\] and eGFR\[MDRD\] equations. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Change From Baseline In Plasma Globotriaosylsphingosine (Lyso-Gb3) To End Of Study
Concentrations of lyso-Gb3 were measured in plasma using a qualified assay. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Change From Baseline In White Blood Cell α-Gal A Activity To End Of Study
The activity of the α-galactosidase A (α-Gal A) enzyme was measured in leukocyte lysate by a validated fluorometric assay method, using 4-methylumbelliferone as a reference. The activity values obtained were normalized to protein (measured using a colorimetric assay). Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Results for male participants are reported. Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Change From Baseline In 24-hour Urine Protein To End Of Study
A 24-hour urine sample was collected to measure 24-hour urine protein. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Change From Baseline In Left Ventricular Mass (LVM) To End Of Study
LVM was measured by echocardiography. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Change From Baseline In Left Ventricular Mass Index (LVMi) To End Of Study
LVMi was measured by echocardiography. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years
Change From Baseline In Patient Reported Quality Of Life To End Of Study, As Assessed By The Short Form-36 (SF-36) Questionnaire
The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health). Scores on each item are summed and averaged (range: 0=worst to 100=best). Scores were normed to the US population. Higher score indicates less disability. A positive change from baseline indicates improvement. Baseline was defined as the data collected in the last visit of the previous (feeder) study. Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
Time frame: Baseline to approximately 30 days after last treatment, median duration of 3.1 years
| Milestone | Migalastat HCl 150 mg |
|---|---|
| Started | 84 |
| Received at least 1 dose of study drug | 84 |
| Completed | 73 |
| Not completed | 11 |
| Withdrew: Adverse event | 1 |
| Withdrew: Met protocol defined stopping criteria | 3 |
| Withdrew: Physician decision | 4 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 2 |
An AE was defined as any untoward medical occurrence in a participant administered migalastat that did not necessarily have a causal relationship with the treatment. Each AE was recorded at time of reporting; visits typically occurred every 6 months. Serious AEs were life threatening or resulted in death, resulted in disability/incapacity, hospitalization or prolonged hospitalization, or a congenital anomaly. The criteria for AE severity were: Mild: awareness of sign or symptom, does not interfere with normal everyday activities; Moderate: discomforting, interferes with normal everyday activities, but able to function; Severe: incapacitating, prevents normal everyday activities or significantly affects clinical status and requires medical intervention. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
| Participants | Migalastat HCl 150 mg |
|---|---|
| Participants with at least 1 AE | 80 |
| Participants with at least 1 serious AE | 26 |
| Participants discontinued due to AEs | 1 |
| Participants with AEs leading to death | 0 |
| Participants with AEs related to study drug | 24 |
| Participants with AEs unrelated to study drug | 56 |
| Participants with at least 1 mild AE | 19 |
| Participants with at least 1 moderate AE | 46 |
| Participants with at least 1 severe AE | 15 |
The annualized rate of change in the eGFR was assessed per participant by the slope of the simple linear regression between the observed values and the assessment times. It was calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (eGFR \[CKD-EPI\]) and the Modification of Diet in Renal Disease (MDRD) equation (eGFR \[MDRD\]). The equations are as follows: eGFR \[MDRD\] = 175 × (1/Serum Creatinine in mg/deciliter\^1.154) × (1/Age in years\^0.203) × 0.742 \[if female\] × 1.212 \[if black\] × 0.808 \[if Japanese\]; eGFR \[CKD-EPI\] = 141 × min(Serum creatinine \[Scr\]/k, 1)α × max(Scr/k, 1) - 1.209 × 0.993Age × 1.018 \[if female\] × 1.159 \[if black\], where Scr is serum creatinine, k is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates the maximum of Scr/k or 1. Participants with at least a Baseline and a post-Baseline value are presented.
| mL/min/1.73 m^2 | Migalastat HCl 150 mg |
|---|---|
| eGFR[MDRD] | -1.6107 ± 5.62761 |
| eGFR[CKD-EPI] | -1.3528 ± 4.84795 |
The change from baseline in eGFR was calculated using eGFR\[CKD-EPI\] and eGFR\[MDRD\] equations. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
| mL/min/1.73 m^2 | Migalastat HCl 150 mg |
|---|---|
| Baseline eGFR[MDRD] | 79.0 ± 22.56 |
| End of Study eGFR[MDRD] | 75.8 ± 22.90 |
| Change from Baseline eGFR[MDRD] | -1.4 ± 10.62 |
| Baseline eGFR[CKD-EPI] | 84.70 ± 23.092 |
| End of Study eGFR[CKD-EPI] | 82.02 ± 23.890 |
| Change from Baseline eGFR[CKD-EPI] | -0.93 ± 9.828 |
Concentrations of lyso-Gb3 were measured in plasma using a qualified assay. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
| nmol/L | Migalastat HCl 150 mg |
|---|---|
| Baseline | 13.317 ± 17.5428 |
| End of Study | 11.758 ± 16.0662 |
| Change from Baseline | -1.054 ± 4.4885 |
The activity of the α-galactosidase A (α-Gal A) enzyme was measured in leukocyte lysate by a validated fluorometric assay method, using 4-methylumbelliferone as a reference. The activity values obtained were normalized to protein (measured using a colorimetric assay). Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Results for male participants are reported. Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
| nmol/hr/mg | Migalastat HCl 150 mg |
|---|---|
| Baseline | 6.882 ± 6.6857 |
| End of Study | 5.290 ± 5.4054 |
| Change from Baseline | -1.375 ± 3.3432 |
A 24-hour urine sample was collected to measure 24-hour urine protein. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
| mg/day | Migalastat HCl 150 mg |
|---|---|
| Baseline | 478.9 ± 948.59 |
| End of Study | 394.0 ± 547.77 |
| Change from Baseline | 5.4 ± 233.49 |
LVM was measured by echocardiography. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
| gram | Migalastat HCl 150 mg |
|---|---|
| Baseline | 178.879 ± 78.6761 |
| End of Study | 157.896 ± 47.9947 |
| Change from Baseline | -0.803 ± 18.8522 |
LVMi was measured by echocardiography. Baseline was defined as the data collected at Month 0, if not available, it was the last visit of the previous (feeder) study if done within 6 months. End of Study was the last recorded observation for each participant (approximately 30 days after last treatment). Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
| g/m^2 | Migalastat HCl 150 mg |
|---|---|
| Baseline | 96.513 ± 36.5691 |
| End of Study | 83.912 ± 22.7633 |
| Change from Baseline | -0.809 ± 11.8056 |
The SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health). Scores on each item are summed and averaged (range: 0=worst to 100=best). Scores were normed to the US population. Higher score indicates less disability. A positive change from baseline indicates improvement. Baseline was defined as the data collected in the last visit of the previous (feeder) study. Only participants with both a Baseline value and an End of Study value were included in the change from baseline analysis.
| units on a scale | Migalastat HCl 150 mg |
|---|---|
| Baseline Physical Functioning | 48.313 ± 9.2345 |
| End of Study Physical Functioning | 46.415 ± 10.2466 |
| Change from Baseline Physical Functioning | -1.276 ± 7.1627 |
| Baseline Role Physical | 46.197 ± 10.0761 |
| End of Study Role Physical | 45.929 ± 10.5723 |
| Change from Baseline Role Physical | 0.390 ± 7.3500 |
| Baseline Bodily Pain | 46.889 ± 10.5983 |
| End of Study Bodily Pain | 46.737 ± 10.3368 |
| Change from Baseline Bodily Pain | 0.425 ± 8.1342 |
| Baseline General Health | 44.016 ± 10.2497 |
| End of Study General Health | 42.352 ± 10.1185 |
| Change from Baseline General Health | -0.811 ± 5.8672 |
| Baseline Vitality | 46.375 ± 11.8451 |
| End of Study Vitality | 45.429 ± 12.4340 |
| Change from Baseline Vitality | -0.674 ± 8.5076 |
| Baseline Social Functioning | 47.433 ± 10.4985 |
| End of Study Social Functioning | 47.648 ± 9.5165 |
| Change from Baseline Social Functioning | 0.401 ± 8.4356 |
| Baseline Role Emotional | 47.547 ± 10.3897 |
| End of Study Role Emotional | 46.141 ± 10.9054 |
| Change from Baseline Role Emotional | -0.929 ± 10.6679 |
| Baseline Mental Health | 48.501 ± 10.6878 |
| End of Study Mental Health | 49.578 ± 10.5732 |
| Change from Baseline Mental Health | 0.872 ± 6.2528 |
| Baseline Physical Component | 46.184 ± 10.2268 |
| End of Study Physical Component | 44.825 ± 10.4292 |
| Change from Baseline Physical Component | -0.508 ± 6.2494 |
| Baseline Mental Component | 47.917 ± 11.5480 |
| End of Study Mental Component | 48.175 ± 10.9497 |
| Change from Baseline Mental Component | 0.187 ± 8.2714 |
Collected over Baseline to up to 4.4 years (includes safety follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Migalastat HCl 150 mg | 0/84 (0%) | 26/84 (31%) | 74/84 (88.1%) |
| Event | Migalastat HCl 150 mg |
|---|---|
| Atrial fibrillationCardiac disorders | 2/84 |
| DehydrationMetabolism and nutrition disorders | 2/84 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/84 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/84 |
| Atrioventricular block completeCardiac disorders | 1/84 |
| Left ventricular hypertrophyCardiac disorders | 1/84 |
| Ventricular tachycardiaCardiac disorders | 1/84 |
| Visual impairmentEye disorders | 1/84 |
| Abdominal painGastrointestinal disorders | 1/84 |
| Abdominal pain upperGastrointestinal disorders | 1/84 |
| Event | Migalastat HCl 150 mg |
|---|---|
| NasopharyngitisInfections and infestations | 17/84 |
| FatigueGeneral disorders | 16/84 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/84 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 14/84 |
| ParaesthesiaNervous system disorders | 13/84 |
| Oedema peripheralGeneral disorders | 12/84 |
| Upper respiratory tract infectionInfections and infestations | 12/84 |
| Urinary tract infectionInfections and infestations | 12/84 |
| OverdoseInjury, poisoning and procedural complications | 12/84 |
| HeadacheNervous system disorders | 12/84 |
All participants who took at least 1 dose of the study drug after they had enrolled into this study.
| Age, Continuous(years) | Migalastat HCl 150 mg |
|---|---|
| Mean | 51.9 ± 12.27 |
| Sex: Female, Male(Participants) | Migalastat HCl 150 mg |
|---|---|
| Female | 50 |
| Male | 34 |
| Ethnicity (NIH/OMB)(Participants) | Migalastat HCl 150 mg |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 41 |
| Unknown or Not Reported | 38 |
| Race (NIH/OMB)(Participants) | Migalastat HCl 150 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 78 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Oct 2019, 55 months.
Results were first posted in Dec 2020, 1 year 1 month after primary completion.
Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 55 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat